Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).

Rhode Island Medicaid Prescription Drug Cost Control Bill

This bill aims to bring more transparency and accountability to how prescription drug costs are managed within Rhode Island's Medicaid program. It targets two key players: Managed Care Organizations (MCOs), which are the health insurance companies that administer Medicaid benefits, and Pharmacy Benefit Managers (PBMs), which are the middlemen companies that MCOs hire to handle prescription drug coverage, negotiate drug prices, and process pharmacy claims. The bill would require these organizations to open their books and follow new rules about how they operate and report their costs.

In practical terms, the bill would impose new reporting and oversight requirements so that state officials can see exactly how much is being spent on prescription drugs, what fees and markups are involved, and whether the savings from drug price negotiations are actually being passed along to the Medicaid program. This kind of oversight is intended to prevent situations where PBMs or MCOs may be retaining cost savings that could otherwise reduce the state's overall Medicaid spending.

The people most directly affected are Rhode Islanders who rely on Medicaid for their health coverage, as well as the companies that manage their prescription drug benefits. If the bill succeeds in controlling costs, it could mean the state spends less on Medicaid drug coverage, potentially freeing up funds for other public services. The bill has been referred to the House Finance Committee, meaning it is still in the early stages of the legislative process.